Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05838625 · ClinicalTrials.gov registry record · Phase 3
Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia
A Phase 3 study, sponsored by Click Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 464
- Enrollment target
NCT05838625: Completed Phase 3 study, sponsored by Click Therapeutics.
NCT05838625 is a Phase 3 study that has completed, run by Click Therapeutics. The registered enrollment target is 464 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (40% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05838625, a Phase 3 study, has completed, sponsored by Click Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 464 participants
- Enrollment target
Study Summary
This study evaluates the efficacy of two prescription digital therapeutics (PDT) in addition to standard of care (SOC) therapy for the treatment of experiential negative symptoms of schizophrenia in late adolescents and adults.
Primary Outcome
Change from baseline to Week 16 in experiential negative symptoms, as assessed by Clinical Assessment Interview for Negative Symptoms, Motivation and Pleasure Scale (CAINS-MAP)
Interventions
- DEVICE Digital Control
- DEVICE CT-155
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 464 participants |
| Start Date | 2023-03-31 |
| Est. Completion | 2025-07-23 |
| Phase | Phase 3 |
What the finished NCT05838625 record still lists
NCT05838625 is an interventional study that assigns participants to a tested intervention. The registered 464 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (40% lower).
The record links to 0 conditions, and to 2 interventions - of which Digital Control is the first listed.
NCT05838625 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05838625 about?
NCT05838625 is a clinical study titled "Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia". This study evaluates the efficacy of two prescription digital therapeutics (PDT) in addition to standard of care (SOC) therapy for the treatment of experiential negative symptoms of schizophrenia in late adolescents and adults.
What is the current status of trial NCT05838625?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 464 participants. The study started on 2023-03-31. Estimated completion is 2025-07-23.
What interventions are being tested in trial NCT05838625?
The interventions under investigation include: Digital Control (DEVICE), CT-155 (DEVICE).
Who is sponsoring clinical trial NCT05838625?
This trial is sponsored by Click Therapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05838625's enrollment target sits among peer trials
464 821st of 2000 higher than 1,180 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04787744 · 464 participants · Phase 2
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
- NCT04855656 · 464 participants · Phase 1
Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors
- NCT06283927 · 464 participants
The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
- NCT06444295 · 464 participants · NA
Testing the Impact of Thrive App Versions on Alcohol Use and Posttraumatic Stress After Recent Sexual Assault
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI